Luciana Borio

American physician and public health administrator

Luciana Borio is a Brazilian-American infectious disease physician and medical/public health administrator.

Luciana Borio
National Security Council Director for Medical and Biodefense Preparedness
In office
2017–2019
PresidentDonald Trump
Preceded byAndrew Garrett
Acting Chief Scientist of the FDA
In office
2015–2017
PresidentBarack Obama and Donald Trump
Preceded byStephen Ostroff
Succeeded byDenise Hinton
Assistant Commissioner of FDA for Counterterrorism Policy
In office
2010–2017
PresidentBarack Obama
Preceded byRADM Boris Lushniak
Succeeded byRADM Carmen Maher
Personal details
BornRio de Janeiro, Brazil
Alma materGeorge Washington University (MD)

She is a vice president at In-Q-Tel.[1] She was Director for Medical and Biodefense Preparedness at the National Security Council,[2] Acting Chief Scientist of the U.S. Food and Drug Administration (FDA),[3] Assistant Commissioner for Counterterrorism Policy of the FDA, and Director of FDA's Office of Counterterrorism and Emerging Threats.[4]

She is known for her work advancing clinical trials,[5][6] the development of medical countermeasures for health emergencies,[7] and the public health responses to Ebola and Zika outbreaks.[8]

On November 9, 2020, U.S. president-elect Joe Biden named Borio to be one of the 13 members of his COVID-19 Advisory Board.[9]

References change

  1. Borio, Luciana; Gottlieb, Scott (January 28, 2020). "Act now to prevent an American epidemic". Wall Street Journal. Retrieved 2020-01-30.
  2. "Key Global Health Positions and Officials in the U.S. Government". Kaiser Family Foundation. Retrieved 2018-07-28.
  3. "Examining the U.S. Public Health Response to the Zika Virus: U.S. Food and Drug Administration Testimony before U.S. House of Representatives". U.S. Food and Drug Administration. Retrieved 2018-07-28.
  4. "Meet Luciana Borio, M.D., Assistant Commissioner for Counterterrorism Policy". U.S. Food and Drug Administration. Retrieved 2013-10-04.
  5. "Luciana Borio: FDA's Role in Increasing Clinical Trial Diversity". U.S. Food and Drug Administration. Retrieved 2018-07-28.
  6. "You may hold the cure for the next epidemic". TEDxUSU. Retrieved 2018-07-28.
  7. "Borio interview". Johns Hopkins University Center for Health Security. Retrieved 2018-07-28.
  8. September 17, 2014, U.S. House of Representatives Committee on Foreign Affairs, Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations hearing entitled “Global Efforts to Fight Ebola”; October 16, 2014, U.S. House of Representatives Energy and Commerce Committee, Subcommittee on Oversight and Investigations hearing entitled “Examining The U.S. Public Health Response to the Ebola Outbreak;” November 19, 2014, U.S. House of Representatives Committee on Energy and Commerce, Subcommittee on Health hearing entitled “Examining Medical Product Development in the Wake of the Ebola Epidemic;” February 26, 2015, U.S. Senate Committee on Health, Education, Labor and Pensions hearing entitled “Medical and Public Health Preparedness and Response: Are We Ready for Future Threats?” March 02, 2016, US House of Representatives Committee on Energy and Commerce, Subcommittee on Oversight and Investigations hearing entitled “Examining the U.S. Public Health Response to the Zika Virus.”
  9. Mucha, Sarah (November 9, 2020). "Biden transition team announces coronavirus advisers, including whistleblower Rick Bright". CNN. Retrieved 9 November 2020.